Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Leukemia, Myeloid, Acute 20Lymphoma, Non-Hodgkin 19Hodgkin Disease 18Multiple Myeloma 17Myelodysplastic Syndromes 16Lymphoma 16Graft vs Host Disease 16Lymphoma, Mantle-Cell 15Leukemia, Lymphocytic, Chronic, B-Cell 15Leukemia 14Sarcoma 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11Glioblastoma 11Tuberous Sclerosis 10Lymphoma, B-Cell, Marginal Zone 10Carcinoma, Renal Cell 10Neoplasms 9Hematologic Neoplasms 9Gliosarcoma 9Carcinoma, Hepatocellular 9Breast Neoplasms 9Brain Neoplasms 9Waldenstrom Macroglobulinemia 8Myeloproliferative Disorders 8Melanoma 8Burkitt Lymphoma 8Recurrence 7Neoplasm Metastasis 7

Interventions

Cannabidiol 2Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sturge-Weber Syndrome × Sirolimus × Clear all
NCT03047980 2021-11-01

Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome

Hugo W. Moser Research Institute at Kennedy Krieger, Inc.

Phase 2/3 Completed
10 enrolled 11 charts

Sturge-Weber Syndrome, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡